A novel approach to inhibiting HIV-1 infection by actively neutralizing the antibodies of reverse transcriptase system

International Conference on HIV/AIDS, STDs, & STIs

October 24-25, 2013 Holiday Inn Orlando International Airport, Orlando, FL, USA

Sherif Salah

Posters: J AIDS Clin Res

Abstract :

H IV infection is frequently reported in Egypt. This study introduces a new approach for HIV eradication based on a new enzyme combination reverse transcriptase and DNA polymerase (VK 25 RD) formula for inhibiting and or preventing the disease. This pilot study was done on five naive patients who were all positive for HIV antibodies, never treated with anti retroviral medications. Those patients were registered and under surveillance by HIV/AIDS Control Department at the Egyptian ministry of Health (MOH). Their immunological data revealed a viral load more than 1000 copies/ml by HIV-RNA-PCR, antibody positive to HIV-1 and CD4 + T-cell values less than 250 cells/μL. All of the patients showed the same clinical symptoms of HIV/AIDS and wrote consent of acceptance to take this combination therapy in the form of subcutaneous injection of 0.1 cc twice daily for 24 weeks. At the end of therapy, all of the above patient's viral loads had become under the detectable limits [less than 16 copies/ ml]; also there was a significant increase of their CD4 cells count over 500 cells/μL. According to these findings, this therapeutic modality was promising for treating HIV-1 disease and human immunodeficiency syndrome

Biography :

Sherif Salah Consultant of clinical immunology vets. Medicine Cairo university, Innovator of three Pharmaceuticals in Egyptian Market , won two International Prize ?Gold Medals? in European and in Italian Exhibition of Creativity and Innovation EUROINVENT and 2 silver Medals in Korea and Moscow in [Antiviral compositions for treatment of HCV & HBV] in 2012. And awarded two patents of invention in treatment of hepatitis C virus, WO 2008/092466 A1, and treatment of liver cancer WO 2009/138094 A1. G.P.O.